Literature DB >> 23324596

The neurodegeneration in Alzheimer disease and the prion protein.

Gianluigi Forloni1, Alessandra Sclip, Tiziana Borsello, Claudia Balducci.   

Abstract

The concept of "prion-like" has been proposed to explain the pathogenic mechanism of the principal neurodegenerative disorders associated with protein misfolding, including Alzheimer disease (AD). Other evidence relates prion protein with AD: the cellular prion protein (PrP(C)) binds β amyloid oligomers, allegedly responsible for the neurodegeneration in AD, mediating their toxic effects. We and others have confirmed the high-affinity binding between β amyloid oligomers and PrP(C), but we were not able to assess the functional consequences of this interaction using behavioral investigations and in vitro tests. This discrepancy rather than being resolved with the classic explanations, differencies in methodological aspects, has been reinforced by new data from different sources. Here we present data obtained with PrP antibody that not interfere with the neurotoxic activity of β amyloid oligomers. Since the potential role of the PrP(C) in the neuronal dysfunction induced by β amyloid oligomers is an important issue, find reasonable explanation of the inconsistent results is needed. Even more important however is the relevance of this interaction in the context of the disease, so as to develop valid therapeutic strategies.

Entities:  

Keywords:  Alzheimer; neurodegeneration; oligomers; prion; therapy

Mesh:

Substances:

Year:  2013        PMID: 23324596      PMCID: PMC3609052          DOI: 10.4161/pri.23286

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  85 in total

1.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation.

Authors:  C Nilsberth; A Westlind-Danielsson; C B Eckman; M M Condron; K Axelman; C Forsell; C Stenh; J Luthman; D B Teplow; S G Younkin; J Näslund; L Lannfelt
Journal:  Nat Neurosci       Date:  2001-09       Impact factor: 24.884

2.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

3.  Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection.

Authors:  Silvio M Zanata; Marilene H Lopes; Adriana F Mercadante; Glaucia N M Hajj; Luciana B Chiarini; Regina Nomizo; Adriana R O Freitas; Ana L B Cabral; Kil S Lee; Maria A Juliano; Elizabeth de Oliveira; Saul G Jachieri; Alma Burlingame; Lan Huang; Rafael Linden; Ricardo R Brentani; Vilma R Martins
Journal:  EMBO J       Date:  2002-07-01       Impact factor: 11.598

4.  The P's and Q's of cellular PrP-Aβ interactions.

Authors:  David Westaway; Jack H Jhamandas
Journal:  Prion       Date:  2012-08-09       Impact factor: 3.931

Review 5.  Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics.

Authors:  Dennis J Selkoe; Dale Schenk
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-01-10       Impact factor: 13.820

6.  Alzheimer's drugs take a new tack.

Authors:  Ewen Callaway
Journal:  Nature       Date:  2012-09-06       Impact factor: 49.962

7.  Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits.

Authors:  L A Holcomb; M N Gordon; P Jantzen; K Hsiao; K Duff; D Morgan
Journal:  Behav Genet       Date:  1999-05       Impact factor: 2.805

8.  The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein.

Authors:  B Vincent; E Paitel; P Saftig; Y Frobert; D Hartmann; B De Strooper; J Grassi; E Lopez-Perez; F Checler
Journal:  J Biol Chem       Date:  2001-07-26       Impact factor: 5.157

9.  Age-dependent cognitive decline in the APP23 model precedes amyloid deposition.

Authors:  Debby Van Dam; Rudi D'Hooge; Matthias Staufenbiel; Chris Van Ginneken; Frans Van Meir; Peter P De Deyn
Journal:  Eur J Neurosci       Date:  2003-01       Impact factor: 3.386

10.  Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss.

Authors:  Yuesong Gong; Lei Chang; Kirsten L Viola; Pascale N Lacor; Mary P Lambert; Caleb E Finch; Grant A Krafft; William L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-18       Impact factor: 11.205

View more
  4 in total

1.  Complex proteinopathy with accumulations of prion protein, hyperphosphorylated tau, α-synuclein and ubiquitin in experimental bovine spongiform encephalopathy of monkeys.

Authors:  Pedro Piccardo; Juraj Cervenak; Ming Bu; Lindsay Miller; David M Asher
Journal:  J Gen Virol       Date:  2014-04-25       Impact factor: 3.891

2.  Single-molecule imaging reveals that small amyloid-β1-42 oligomers interact with the cellular prion protein (PrP(C)).

Authors:  Kristina A Ganzinger; Priyanka Narayan; Seema S Qamar; Laura Weimann; Rohan T Ranasinghe; Adriano Aguzzi; Christopher M Dobson; James McColl; Peter St George-Hyslop; David Klenerman
Journal:  Chembiochem       Date:  2014-10-07       Impact factor: 3.164

Review 3.  Amyloid-beta: a crucial factor in Alzheimer's disease.

Authors:  Saeed Sadigh-Eteghad; Babak Sabermarouf; Alireza Majdi; Mahnaz Talebi; Mehdi Farhoudi; Javad Mahmoudi
Journal:  Med Princ Pract       Date:  2014-11-27       Impact factor: 1.927

Review 4.  Alzheimer's Disease, Oligomers, and Inflammation.

Authors:  Gianluigi Forloni; Claudia Balducci
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.